Charles J. Democko

Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA.

Signature Therapeutics, Inc. develops and manufactures pharmaceutical products. It focuses on developing medications for use in pain management and ADHD. Its proprietary BIO-MD platform is designed to deter prescription drug abuse by virtue of strong chemical bonds within the prodrug and also offers solution to the ongoing epidemic of prescription opioid drug abuse. The company was founded by Steven L. Shafer in 2004 and is headquartered in Palo Alto, CA.

Connetics Corp. develops and commercializes dermatology products. The firm offers remedies for psoriasis in adults, eczema, seborrheic dermatitis, and acne. The company was founded in 1993 and is headquartered in Palo Alto, CA.

Catalyst Biosciences, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of novel medicines to address serious medical conditions. The company was founded on March 7, 1997 and is headquartered in South San Francisco, CA.